Working… Menu

Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00394173
Recruitment Status : Completed
First Posted : October 31, 2006
Last Update Posted : February 27, 2017
Information provided by:

Brief Summary:
The purpose of this study is to evaluate the efficacy of DNK333 compared to placebo for relieving symptoms of IBS-D in female patients.

Condition or disease Intervention/treatment Phase
Irritable Bowel Syndrome With Diarrhea (IBS-D) Drug: DNK333 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of DNK333 25mg b.i.d. Given Orally for 4 Weeks in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
Study Start Date : September 2006
Actual Primary Completion Date : October 2007
Actual Study Completion Date : October 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diarrhea

Arm Intervention/treatment
Experimental: 1 Drug: DNK333
DNK333 25mg b.i.d. given orally for 4 weeks

Placebo Comparator: 2 Drug: Placebo
Matching placebo

Primary Outcome Measures :
  1. Satisfactory relief of IBS-related abdominal pain/discomfort [ Time Frame: 4 weeks ]
  2. Satisfactory relief of overall IBS-D symptoms [ Time Frame: 4 weeks ]

Secondary Outcome Measures :
  1. Occurrence and control of bowel urgency [ Time Frame: 4 weeks ]
  2. Change in stool frequency [ Time Frame: 4 weeks ]
  3. Severity of abdominal bloating [ Time Frame: 4 weeks ]
  4. Severity of abdominal pain/discomfort [ Time Frame: 4 weeks ]
  5. Safety [ Time Frame: 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female

Inclusion criteria:

  • Women of 18 - 65 years of age with IBS-D as defined by the Rome II criteria.
  • The Rome II criteria is a system used for diagnosing functional gastrointestinal disorders such as irritable bowel syndrome. It involves completing of a questionnaire about gastrointestinal symptoms.
  • Patients who are 50 years of age and older must have had a colonoscopy OR a flexible sigmoidoscopy plus a double-contrast barium enema within the past 5 years, which demonstrated no clinically significant findings.
  • Clinically significant findings may include but are not limited to malignant tumors, multiple (≥3) or advanced adenomas, inflammatory bowel disease, diverticulitis, ischaemic colitis, lymphocytic colitis, or collagenous colitis.
  • Patients must report ≥ 3 days with IBS-related abdominal pain/discomfort plus at least 3 days of 2 or more of the following events during the baseline period:
  • ≥ 3 bowel movements/day
  • Bowel urgency
  • Loose or watery stool

Exclusion Criteria:

  • Patients who answer "yes" to either or both of the two weekly satisfaction questions during the baseline period. The questions are: (1) Over the past week did you have satisfactory relief of your IBS-related abdominal pain/discomfort? (2) Over the last week did you have satisfactory relief of your overall IBS-D symptoms?
  • Patients with hard or lumpy stools for more than one day during the baseline period.
  • Lactose intolerant patients relieved on a lactose free diet.
  • Use of antidepressants (tricyclic, SSRI etc), opioid analgesic drugs or drugs specifically affecting bowel motility during the course of the trial.
  • Women of child-bearing potential who do not use an acceptable methods of contraception.
  • Pregnant or nursing (lactating) women.

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00394173

Layout table for location information
United States, Arizona
Investigative Site
Tucson, Arizona, United States, 85712
United States, Arkansas
Investigative Site
North Little Rock, Arkansas, United States, 72114
United States, California
Investigative Site
Los Angeles, California, United States, 90045-3119
Investigative Site
Orange, California, United States, 92869
Investigative Site
Riverside, California, United States, 92506
Investigative Site
Sacramento, California, United States, 95825
Investigative Site
San Diego, California, United States, 92108
United States, Colorado
Investigative Site
Colorado Springs, Colorado, United States, 80904
United States, Connecticut
Investigative Site
Bristol, Connecticut, United States, 06010
Investigative Site
Hartford, Connecticut, United States, 06010
United States, Florida
Investigative Site
Boca Raton, Florida, United States, 33486
Investigative Site
Gainesville, Florida, United States, 32256
Investigative Site
Hollywood, Florida, United States, 33021
Investigative Site
Jacksonville, Florida, United States, 782091744
Investigative Site
Miami, Florida, United States, 33173
Investigative Site
New Smyrna Beach, Florida, United States, 32168-7327
Investigative Site
Tampa, Florida, United States, 33607
United States, Illinois
Investigative Site
Arlington Heights, Illinois, United States, 60005
Investigative Site
Rockford, Illinois, United States, 61107
United States, Massachusetts
Investigative Site
Boston, Massachusetts, United States, 02215
Investigative Site
Wellesley Hills, Massachusetts, United States, 02481-2106
United States, Missouri
Investigative Site
Mexico, Missouri, United States, 65265-3726
United States, New York
Investigative Site
Buffalo, New York, United States, 14215
Investigative Site
Great Neck, New York, United States, 11023-2432
United States, North Carolina
Investigative Site
Elkin, North Carolina, United States, 28621
United States, Ohio
Investigative Site
Cincinatti, Ohio, United States, 45219
United States, Oklahoma
Investigative Site
Oklahoma City, Oklahoma, United States, 73104
United States, Oregon
Investigative Site
Portland, Oregon, United States, 97220
United States, Tennessee
Investigative Site
Chattanooga, Tennessee, United States, 37404
United States, Texas
Investigative Site
Lake Jackson, Texas, United States, 77566
Investigative Site
San Antonio, Texas, United States, 78209-1744
United States, Utah
Investigative Site
Salt Lake City, Utah, United States, 84102
United States, Virginia
Investigative Site
Chesapeake, Virginia, United States, 23320-1706
United States, Washington
Investigative Site
Bellevue, Washington, United States, 98004
Investigative Site
Everett, Washington, United States, 98208
Investigative Site
Monroe, Washington, United States, 98208
Investigative Site
Seattle, Washington, United States, 98101
Canada, Alberta
Investigative Site
Calgary, Alberta, Canada, T2N 4N1
Canada, Newfoundland and Labrador
Investigative Site
St John's, Newfoundland and Labrador, Canada, A1E 2E2
Canada, Ontario
Investigative Site
Hamilton, Ontario, Canada, L8N 3Z5
Canada, Quebec
Investigative Site
Montreal, Quebec, Canada, H2X 3J4
Investigative Site
Sherbrooke, Quebec, Canada, J1H 4J6
Investigative Site
Quebec, Canada, G1S 4L8
Sponsors and Collaborators
Layout table for investigator information
Study Chair: Novartis Pharmaceuticals Corp. NPC
Publications of Results:
Layout table for additonal information Identifier: NCT00394173    
Other Study ID Numbers: CDNK333B2202
First Posted: October 31, 2006    Key Record Dates
Last Update Posted: February 27, 2017
Last Verified: February 2017
Keywords provided by Novartis:
gastrointestinal functional disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Irritable Bowel Syndrome
Pathologic Processes
Signs and Symptoms, Digestive
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases